+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the use of delgocitinib cream applied twice daily to treat adults with mild to severe lichen sclerosus LS, focusing mainly on female participants since LS is more common in females. This Phase 3 trial is designed to assess the efficacy and safety of delgocitinib in comparison to a cream vehicle over a long period. The study includes two parts Part 1 enrolls females to determine the best dose, and Part 2 enrolls both males and females to further evaluate safety and efficacy. Participants will be assigned randomly to receive either delgocitinib cream at specified doses or a cream vehicle. Treatments are applied twice daily during an initial 12-week period followed by a continuation treatment period lasting 40 weeks. Various dosing regimens are used across groups, including delgocitinib cream alone, cream vehicle alone, or combinations transitioning between the two during the study. Male participants will be included in a substudy to evaluate delgocitinibs effects in men. During the trial, participants will attend clinic visits and undergo assessments including measurement of skin condition severity using the IGA-LS score, clinical lichen sclerosus score CLISSCO, and patient-reported scales for skin pain and itch. Quality of life related to vulvar symptoms will also be monitored. Safety is carefully tracked through adverse event reporting and laboratory tests throughout the study, which lasts from 55 to 60 weeks per participant. The primary outcome is the number of participants achieving a specific improvement in LS severity at week 12.

Age: 18Years +All GendersPhase 3
33 locations
G

Actively Recruiting

Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.

Age: 12Years +All Genders
116 locations
S

Actively Recruiting

Researchers are evaluating LY4005130, an intravenous drug, to see how well it is tolerated and what side effects may occur in adults with non-segmental vitiligo NSV. This randomized, double-blind, placebo-controlled study compares LY4005130 to a placebo over about 48 weeks, including screening. Participants must have NSV diagnosed for at least 3 months with specific body surface area involvement. Participants receive either LY4005130 or placebo intravenously during the treatment period. The study includes a 24-week treatment phase where the drug or placebo is administered, and blood tests are done to understand how the body processes the drug and how it affects the skin condition. The study drug is given through the vein in the arm. During the study, participants will have assessments including blood tests, skin evaluations using Vitiligo Area Scoring Indexes F-VASI and T-VASI, and skin biopsies to measure gene expression changes. Researchers will monitor safety, drug levels in the blood, and treatment effects up to 48 weeks. The main outcome is the percentage of participants achieving significant improvement in facial vitiligo area at week 24.

Age: 18Years - 75YearsAll GendersPhase 2
35 locations
S

Actively Recruiting

Researchers are evaluating the investigational drug SPY072 in adults aged 18 to 75 with moderate to severe hidradenitis suppurativa HS who are also receiving advanced standard of care treatment. This Phase 2, multicenter, randomized, double-blind study aims to assess whether SPY072 can improve symptoms of HS compared to placebo while continuing standard treatment. The study will also monitor safety and how long any treatment effects last. Participants will be randomly assigned to receive either SPY072 or a matching placebo, both given as subcutaneous injections, alongside bimekizumab, an advanced standard of care medication. The treatment period lasts 16 weeks, after which participants enter a follow-up phase to evaluate ongoing safety and durability of response. During the study, participants will undergo regular assessments including clinical evaluations of HS lesions and response to treatment. Researchers will measure outcomes such as the percentage of participants achieving a significant clinical response at Week 16. Safety monitoring will continue up to 52 weeks, and participants progress will be closely tracked throughout the treatment and follow-up periods, which may last until the study ends in mid-2028.

Age: 18Years - 75YearsAll GendersPhase 2
34 locations
E

Actively Recruiting

Researchers are studying the effects of Deucravacitinib BMS-986165 in adolescents aged 12 to 17 years with moderate to severe plaque psoriasis. The study aims to assess the drugs effectiveness, safety, and how it behaves in the body. This phase 3 trial is designed as a randomized, double-blind, placebo-controlled investigation to provide clear evidence of the drugs impact in this younger population. Participants are randomly assigned to receive either Deucravacitinib or a placebo following specified dosing schedules. The study involves a parallel group design where the treatment is given on specified days. The trial will monitor participants closely over time to evaluate treatment responses and any side effects, especially focusing on improvements in psoriasis severity and skin condition. During the study, participants will have regular assessments including measurement of psoriasis severity by Psoriasis Area and Severity Index PASI and Physicians Global Assessment sPGA, body surface area affected, itch severity, and quality of life. Safety monitoring includes checking for adverse events, laboratory tests, physical exams, vital signs, and vaccine antibody levels. The study also tracks growth and sexual maturation over up to five years, providing long-term data on drug safety and participant health.

Age: 12Years - 17YearsAll GendersPhase 3
133 locations
E

Actively Recruiting

Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.

Age: 12Years - 63YearsAll GendersPhase 3
272 locations
R

Actively Recruiting

Researchers are evaluating the efficacy and safety of SAR445399, a drug administered by injection, in adults with moderate to severe hidradenitis suppurativa. This multinational, randomized, double-blind, placebo-controlled Phase 2 study aims to compare two different doses of SAR445399 with a placebo to find the best dose for treating this condition. Participants will be randomly assigned to receive one of two SAR445399 dose regimens or a matching placebo. The treatment period lasts 32 weeks, including a 16-week initial double-blind phase followed by a 16-week treatment-blinded extension period. The total study duration for each participant is up to 46 weeks, with a total of 16 study visits scheduled throughout this time. During the study, participants will be monitored through various assessments including clinical response measures such as Hidradenitis Suppurativa Clinical Response HiSCR levels, severity scoring, skin pain ratings, quality of life questionnaires, laboratory tests, vital signs, and electrocardiograms. Researchers will also track drug concentrations and immune responses. Safety will be closely monitored throughout the study and extension period to evaluate any adverse events or significant changes in health.

Age: 18Years +All GendersPhase 2
86 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.

Age: 40Years +All GendersPhase 3
411 locations
E

Actively Recruiting

Healthy Volunteer

This research aims to evaluate how adding two new questions and pictures to the Psoriasis Epidemiology Screening Tool PEST affects the potential diagnosis of psoriatic arthritis PsA in adults with moderate-to-severe plaque psoriasis PsO in Canada. The study focuses on patients who may need biologic Disease-Modifying Antirheumatic Drugs bDMARDs treatment and seeks to improve early detection of PsA. The study is prospective and involves multiple centers. Participants will first complete a modified PEST screening questionnaire, called PESTpictures2, at their initial dermatologist visit. This version includes the original 5 questions, two additional questions about morning stiffness and nighttime pain, and pictures to help patients identify symptoms like swollen joints and fingernail changes. Those who screen positive will have a follow-up visit with a rheumatologist for a thorough PsA diagnosis. At the end of the study, a remote visit with the dermatologist will record the participants bDMARD treatment choice and status. Patients will be enrolled for up to 120 days. During the study, participants will complete questionnaires and undergo assessments by dermatologists and rheumatologists. Researchers will measure the accuracy of the modified screening tool in predicting PsA, patient experience with the questionnaire, and characteristics of those with positive or negative screening results. Safety and treatment decisions related to bDMARDs will also be monitored. The main outcome is the positive predictive value of the screening tool within about one year.

Age: 18Years +All GendersPhase Not Applicable
30 locations
N

Actively Recruiting

Nephrotic Syndrome, including Minimal Change Disease MCD, Focal Segmental Glomerulosclerosis FSGS, and Membranous Nephropathy MN, causes a significant health and financial burden, representing about 12% of end-stage renal disease cases. Current treatments often lack a clear biological basis and can be toxic, with limited effectiveness. This trial aims to better understand these rare kidney diseases by collecting long-term observational data and biological samples through the Nephrotic Syndrome Study Network, a collaborative research consortium. Participants are grouped into cohorts based on biopsy-confirmed diagnoses of FSGSMCD or MN, or other glomerulopathies, with some pediatric participants included without biopsy if meeting specific clinical criteria. Patients scheduled for clinically indicated kidney biopsies will be asked to consent to an additional biopsy sample for research. The study is observational and follows patients over time without providing experimental treatments. Throughout the study, participants undergo regular evaluations including kidney function and protein excretion measurements, quality of life assessments, and monitoring for serious health events such as infections, hospitalizations, and complications related to kidney disease. The primary outcomes focus on changes in urinary protein levels and kidney function over 60 months, with secondary outcomes tracking quality of life and other health events. Participants will be observed for up to several years to gather comprehensive data on disease progression and outcomes.

Age: 0 - 80YearsAll Genders
44 locations

1-10 of 17

1